Robin J. Dart
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort.
Journal: Crohn's & colitis 360
Published: October 29, 2025
Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.
Journal: Journal of Crohn's & colitis
Published: September 02, 2025
ILC3s mediate intestinal immune-epithelial interactions via TGF-β1 activation.
Journal: Mucosal immunology
Published: April 29, 2025
Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease.
Journal: Science (New York, N.Y.)
Published: September 14, 2023
DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making.
Journal: Journal of Crohn's & colitis
Published: May 12, 2023
Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease.
Journal: Alimentary pharmacology & therapeutics
Published: April 13, 2023
IFN-γ-dependent interactions between tissue-intrinsic γδ T cells and tissue-infiltrating CD8 T cells limit allergic contact dermatitis.
Journal: The Journal of allergy and clinical immunology
Published: January 16, 2023
Editorial: protecting hypoxia-inducible factor-1α and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis?
Journal: Alimentary pharmacology & therapeutics
Published: March 04, 2022
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD - Challenges and Future Directions.
Journal: Journal of Crohn's & colitis
Published: March 30, 2021
Vedolizumab Dose Escalation: In for a Penny, in for a Pound?
Journal: Digestive diseases and sciences
Published: August 25, 2020
Last Updated: 09/26/2026